Introduction – Company Background
GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.
With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.
With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.
From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.
At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.
By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.
Core Strengths in Insole Manufacturing
At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.
Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.
We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.
With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.
Customization & OEM/ODM Flexibility
GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.
Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.
With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.
Quality Assurance & Certifications
Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.
We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.
Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.
ESG-Oriented Sustainable Production
At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.
To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.
We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.
Let’s Build Your Next Insole Success Together
Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.
From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.
Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.
🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw
Indonesia athletic insole OEM supplier
Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.
With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Taiwan anti-odor insole OEM processing factory
Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.
We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.ODM pillow factory in Thailand
At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Thailand graphene material ODM solution
📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Arch support insole OEM from Indonesia
Using an approach based on the CRISPR gene-editing system, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells. Credit: Matthew Daniels, edited by MIT News A technique has been developed by researchers that could help fine-tune the production of monoclonal antibodies and other useful proteins. MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells using an approach based on CRISPR proteins. This technique could be used to precisely tune the production of useful proteins, including the monoclonal antibodies used to treat cancer and other diseases. It could also precisely calibrate other aspects of cellular behavior. In their new study, the researchers showed that this system can work in a variety of mammalian cells, with very consistent results. The paper describing the results was published recently in the journal Nature Communications. “It’s a highly predictable system that we can design up front and then get the expected outcome,” says William C.W. Chen, a former MIT research scientist. “It’s a very tunable system and suitable for many different biomedical applications in different cell types.” Chen, who is now an assistant professor of biomedical sciences at the University of South Dakota, is one of the lead authors of the new study, along with former MIT Research Scientist Leonid Gaidukov and postdoc Yong Lai. Senior author Timothy Lu led the research as an MIT associate professor of biological engineering and of electrical engineering and computer science. Gene Control Many therapeutic proteins, including monoclonal antibodies, are produced in large bioreactors containing mammalian cells that are engineered to generate the desired protein. Several years ago, researchers in MIT’s Synthetic Biology Center, including Lu’s lab, began working with Pfizer Inc. on a project to develop synthetic biology tools that could be used to boost the production of these useful proteins. To do so, the researchers targeted the promoters of the genes they wanted to upregulate. In all mammalian cells, genes have a promoter region that binds to transcription factors — proteins that initiate the transcription of the gene into messenger RNA. In previous work, scientists have designed synthetic transcription factors, including proteins called zinc fingers, to help activate target genes. However, zinc fingers and most other types of synthetic transcription factors have to be redesigned for each gene that they target, making them challenging and time-consuming to develop. In 2013, researchers in Lu’s lab developed a CRISPR-based transcription factor that allowed them to more easily control transcription of naturally occurring genes in mammalian and yeast cells. In the new study, the researchers set out to build on that work to create a library of synthetic biological parts that would allow them to deliver a transgene — a gene not normally expressed by the cell — and precisely control its expression. “The idea is to have a full-spectrum synthetic promoter system that can go from very low to very high, to accommodate different cellular applications,” Chen says. The system that the researchers designed includes several components. One is the gene to be transcribed, along with an “operator” sequence, which consists of a series of artificial transcription factor binding sites. Another component is a guide RNA that binds to those operator sequences. Lastly, the system also includes a transcription activation domain attached to a deactivated Cas9 protein. When this deactivated Cas9 protein binds to the guide RNA at the synthetic promoter site, the CRISPR-based transcription factor can turn on gene expression. The promoter sites used for this synthetic system were designed to be distinct from naturally occurring promoter sites, so that the system won’t affect genes in the cells’ own genomes. Each operator includes between two and 16 copies of the guide RNA binding site, and the researchers found that their system could initiate gene transcription at rates that linearly correspond to the number of binding sites, allowing them to precisely control the amount of the protein produced. High Consistency The researchers tested their system in several types of mammalian cells, including Chinese hamster ovary (CHO) cells, which are commonly used to produce therapeutic proteins in industrial bioreactors. They found very similar results in CHO cells and the other cells they tested, including mouse and rat myoblasts (precursors to muscle cells), human embryonic kidney cells, and human induced pluripotent stem cells. “The system has very high consistency over different cell types and different target genes,” Chen says. “This is a good starting point for thinking about regulating gene expression and cell behavior with a highly tunable, predictable artificial system.” After first demonstrating that they could use the new system to induce cells to produce expected amounts of fluorescent proteins, the researchers showed they could also use it to program the production of the two major segments of a monoclonal antibody known as JUG444. The researchers also programmed CHO cells to produce different quantities of a human antibody called anti-PD1. When human T cells were exposed to these cells, they became more potent tumor cell killers if there was a larger amount of the antibody produced. Although the researchers were able to obtain a high yield of the desired antibodies, further work would be needed to incorporate this system into industrial processes, they say. Unlike the cells used in industrial bioreactors, the cells used in this study were grown on a flat surface, rather than in a liquid suspension. “This is a system that is promising to be used in industrial applications, but first we have to adapt this into suspended cells, to see if they make the proteins the same way. I suspect it should be the same, because there’s no reason that it shouldn’t, but we still need to test it,” Chen says. Reference: “A synthetic transcription platform for programmable gene expression in mammalian cells” by William C. W. Chen, Leonid Gaidukov, Yong Lai, Ming-Ru Wu, Jicong Cao, Michael J. Gutbrod, Gigi C. G. Choi, Rachel P. Utomo, Ying-Chou Chen, Liliana Wroblewska, Manolis Kellis, Lin Zhang, Ron Weiss and Timothy K. Lu, 18 October 2022, Nature Communications. DOI: 10.1038/s41467-022-33287-9 The research was funded by the Pfizer-MIT RCA Synthetic Biology Program, the National Science Foundation, the National Institutes of Health, the University of South Dakota Sanford School of Medicine, an NIH Ruth L. Kirschstein NRSA postdoctoral fellowship, and the U.S. Department of Defense.
The electrical field-guided migration of Salmonella. Credit: UC Regents Research reveals an electric current in the gut that can attract pathogens such as Salmonella. UC Davis scientists found that Salmonella uses electric signals in the gut to invade the body, a process called galvanotaxis, offering new insights into bacterial infections and potential treatments for diseases like IBD. How do bad bacteria find entry points in the body to cause infection? This question is fundamental for infectious disease experts and people who study bacteria. Harmful pathogens, like Salmonella, find their way through a complex gut system where they are vastly outnumbered by good microbes and immune cells. Still, the pathogens navigate to find vulnerable entry points in the gut that would allow them to invade and infect the body. A team of UC Davis Health researchers has discovered a novel bioelectrical mechanism these pathogens use to find these openings. Their study was published in Nature Microbiology. Bacteria breaking through the gated gut Salmonella causes about 1.35 million illnesses and 420 deaths in the United States every year. To infect someone, this pathogen needs to cross the gut-lining border. “When ingested, Salmonella find their way to the intestines. There, they are vastly outnumbered by over 100 trillion good bacteria (known as commensals). They are facing the odds of one in a million!” said the study’s lead author Yao-Hui Sun. Sun is a research scientist affiliated with the Departments of Internal Medicine, Ophthalmology and Vision Science, and Dermatology. To learn how Salmonellae find their way in the intestine, the researchers observed the movement of S. Typhimurium bacteria (a strain of Salmonella) and compared it to that of a harmless strain of Escherichia coli (E. coli) bacteria. Navigating a complex gut landscape The intestine has a very complex landscape. Its epithelial structure includes villus epithelium and follicle-associated epithelium (FAE). Villus epithelium is made of absorptive cells (enterocytes) with protrusions that help with nutrient absorption. FAE, on the other hand, contains M cells overlying small clusters of lymphatic tissue known as Peyer’s patches. These M cells are tasked with antigen sampling. They act as the immune system’s first line of defense against microbial and dietary antigens. Findings The research that was done on a mouse model showed that Salmonellae detect electric signals in FAE. They move toward this part of the gut where they find openings through which they can enter. This process of cell movement in response to electric fields is called galvanotaxis, or electrotaxis. “Our study found that this ‘entry point’ has electric fields that the Salmonella bacteria take advantage of to pass,” said the study’s senior author Min Zhao. Zhao is a UC Davis professor of ophthalmology and dermatology and a researcher affiliated with the Institute for Regenerative Cures. The study also showed that E. coli and Salmonella respond differently to bioelectric fields. They have opposite responses to the same electric cue. While E. coli clustered next to the villi, Salmonella gathered to FAE. The study detected electric currents that loop by entering the absorptive villi and exiting the FAE. “Notably, the bioelectric field in the gut epithelia is configured in a way that Salmonellae take advantage of to be sorted to the FAE and less so for E. coli,” explained Sun. “The pathogen seems to prefer the FAE as a gateway to invade the host and cause infections.” Previous studies have indicated that bacteria use chemotaxis to move around. With chemotaxis, the bacteria sense chemical gradients and move towards or away from specific compounds. But the new study suggests that the galvanotaxis of Salmonella to the FAE does not occur through chemotaxis pathways. “Our study presents an alternative or a complementary mechanism in modulating Salmonella targeting to the gut epithelium,” Zhao said. Potential link to IBD and other gut disorders The study might have the potential to explain complex chronic diseases, such as inflammatory bowel disease (IBD). “This mechanism represents a new pathogen-human body “arms race” with potential implications for other bacterial infections as well as prevention and treatment possibilities,” Zhao said. “It is believed that the root cause of IBD is an excessive and abnormal immune response against good bacteria. It will be interesting to learn whether patients prone to have IBD also have aberrant bioelectric activities in gut epithelia.” Reference: “Gut epithelial electrical cues drive differential localization of enterobacteria” by Yaohui Sun, Fernando Ferreira, Brian Reid, Kan Zhu, Li Ma, Briana M. Young, Catherine E. Hagan, Renée M. Tsolis, Alex Mogilner and Min Zhao, 20 August 2024, Nature Microbiology. DOI: 10.1038/s41564-024-01778-8 Funding: National Institutes of Health, Defense Advanced Research Projects Agency, Fundação para a Ciência e Tecnologia, Air Force Office of Scientific Research, Office of Naval Research, National Eye Institute.
The waters of Palau harbor highly venomous sea snails. Credit: Safavi Lab Cone snail venom contains consomatin, a toxin that could lead to better, longer-lasting drugs for diabetes and hormone-related diseases by mimicking somatostatin. A new study published in Nature Communications reveals the toxin from one of the most venomous animals on the planet may hold the key to improving drugs for diabetes and hormone disorders. An international team of scientists led by the University of Utah identified a component within the venom of a deadly marine cone snail, the geography cone, that mimics a human hormone called somatostatin, which regulates the levels of blood sugar and various hormones in the body. The hormone-like toxin’s specific, long-lasting effects, which help the snail hunt its prey, could also help scientists design better drugs for hormone disorders and diabetes. Ho Yan Yeung, PhD, first author on the study (left) and Thomas Koch, PhD, also an author on the study (right) examine a freshly-collected batch of cone snails. Credit: Safavi Lab Blueprint for Better Drugs The somatostatin-like toxin the researchers identified could provide invaluable insights into new medications for diabetes and hormone disorders. Somatostatin acts like a brake pedal for many processes in the human body, preventing blood sugar, various hormones, and many other important molecules from rising to dangerously high levels. The researchers found the cone snail toxin, called consomatin, works similarly, —but consomatin is more stable and specific than the human hormone, which makes it a promising blueprint for drug design. By measuring how consomatin interacts with somatostatin’s targets in human cells in a dish, the researchers found that consomatin interacts with one of the same proteins that somatostatin does. But while somatostatin directly interacts with several proteins, consomatin only interacts with one. This fine-tuned targeting means that the cone snail toxin affects hormone levels and blood sugar levels but not the levels of many other molecules. Helena Safavi, PhD, senior author on the study, diving during a cone snail collection mission. Credit: Helena Safavi In fact, the cone snail toxin is more precisely targeted than the most specific synthetic drugs designed to regulate hormone levels, such as drugs that regulate growth hormone. Such drugs are an important therapy for people whose bodies overproduce growth hormones. Consomatin’s effects on blood sugar could make it dangerous to use as a therapeutic, but by studying its structure, researchers could start to design drugs for endocrine disorders that have fewer side effects. Consomatin is more specific than top-of-the-line synthetic drugs—and it also lasts far longer in the body than the human hormone, thanks to the inclusion of an unusual amino acid that makes it difficult to break down. This is a useful feature for pharmaceutical researchers looking for ways to make drugs that will have long-lasting benefits. A freshly-collected batch of venomous cone snails. Credit: Safavi Lab Learning from Cone Snails Finding better drugs by studying deadly venoms may seem unintuitive, but Helena Safavi, PhD, associate professor of biochemistry in the Spencer Fox Eccles School of Medicine (SFESOM) at the University of Utah and the senior author on the study, explains that the toxins’ lethality is often aided by pinpoint targeting of specific molecules in the victim’s body. That same precision can be extraordinarily useful when treating disease. “Venomous animals have, through evolution, fine-tuned venom components to hit a particular target in the prey and disrupt it,” Safavi says. “If you take one individual component out of the venom mixture and look at how it disrupts normal physiology, that pathway is often really relevant in disease.” For medicinal chemists, “it’s a bit of a shortcut.” Ho Yan Yeung, PhD, first author on the study, hunts for venomous sea snails in the shallow reefs of Palau. Credit: Safavi Lab Consomatin shares an evolutionary lineage with somatostatin, but over millions of years of evolution, the cone snail turned its own hormone into a weapon. For the cone snail’s fishy prey, consomatin’s deadly effects hinge on its ability to prevent blood sugar levels from rising. And importantly, consomatin doesn’t work alone. Safavi’s team had previously found that cone snail venom includes another toxin that resembles insulin, lowering the level of blood sugar so quickly that the cone snail’s prey becomes nonresponsive. Then, consomatin keeps blood sugar levels from recovering. The waters of Palau harbor highly venomous sea snails that scientists are studying to develop better medicines. Credit: Safavi Lab Evolutionary Insights from Cone Snails “We think the cone snail developed this highly selective toxin to work together with the insulin-like toxin to bring down blood glucose to a really low level,” says Ho Yan Yeung, PhD, a postdoctoral researcher in biochemistry in SFESOM and the first author on the study. The fact that multiple parts of the cone snail’s venom target blood sugar regulation hints that the venom could include many other molecules that do similar things. “It means that there might not only be insulin and somatostatin-like toxins in the venom,” Yeung says. “There could potentially be other toxins that have glucose-regulating properties too.” Such toxins could be used to design better diabetes medications. It may seem surprising that a snail is able to outperform the best human chemists at drug design, but Safavi says that the cone snails have evolutionary time on their side. “We’ve been trying to do medicinal chemistry and drug development for a few hundred years, sometimes badly,” she says. “Cone snails have had a lot of time to do it really well.” Or, as Yeung puts it, “Cone snails are just really good chemists.” Reference: “Fish-hunting cone snail disrupts prey’s glucose homeostasis with weaponized mimetics of somatostatin and insulin” by Ho Yan Yeung, Iris Bea L. Ramiro, Daniel B. Andersen, Thomas Lund Koch, Alexander Hamilton, Walden E. Bjørn-Yoshimoto, Samuel Espino, Sergey Y. Vakhrushev, Kasper B. Pedersen, Noortje de Haan, Agnes L. Hipgrave Ederveen, Baldomero M. Olivera, Jakob G. Knudsen, Hans Bräuner-Osborne, Katrine T. Schjoldager, Jens Juul Holst and Helena Safavi-Hemami, 20 August 2024, Nature Communications. DOI: 10.1038/s41467-024-50470-2
DVDV1551RTWW78V
Indonesia foot care insole ODM expert 》helping your brand lead with innovation and integrityOne-stop OEM/ODM solution provider Indonesia 》helping your business stand out with material and functional innovationGraphene insole manufacturing factory in Taiwan 》reducing complexity, increasing product value